Joint inference for competing risks data using multiple endpoints.
Jiyang WenChen HuMei-Cheng WangPublished in: Biometrics (2022)
Competing risks data are commonly encountered in randomized clinical trials and observational studies. This paper considers the situation where the ending statuses of competing events have different clinical interpretations and/or are of simultaneous interest. In clinical trials, often more than one competing event has meaningful clinical interpretations even though the trial effects of different events could be different or even opposite to each other. In this paper, we develop estimation procedures and inferential properties for the joint use of multiple cumulative incidence functions (CIFs). Additionally, by incorporating longitudinal marker information, we develop estimation and inference procedures for weighted CIFs and related metrics. The proposed methods are applied to a COVID-19 in-patient treatment clinical trial, where the outcomes of COVID-19 hospitalization are either death or discharge from the hospital, two competing events with completely different clinical implications.
Keyphrases
- clinical trial
- coronavirus disease
- sars cov
- phase ii
- phase iii
- study protocol
- big data
- electronic health record
- single cell
- risk factors
- human health
- healthcare
- emergency department
- magnetic resonance imaging
- metabolic syndrome
- machine learning
- risk assessment
- contrast enhanced
- combination therapy
- cross sectional
- respiratory syndrome coronavirus
- insulin resistance
- deep learning
- drug induced